Leerink Partnrs Forecasts Geron's Q3 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Geron in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.03) EPS.

Several other brokerages also recently issued reports on GERN. Stifel Nicolaus lowered their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. B. Riley lowered shares of Geron from a "buy" rating to a "neutral" rating and cut their price objective for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 price objective on shares of Geron in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Finally, Barclays reaffirmed an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $5.06.

Geron Stock Performance

Shares of NASDAQ GERN traded down $0.01 during trading hours on Monday, hitting $1.19. 5,926,391 shares of the company's stock were exchanged, compared to its average volume of 11,566,522. Geron has a 1-year low of $1.17 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock has a market capitalization of $757.93 million, a price-to-earnings ratio of -3.72 and a beta of 0.76. The company's 50-day moving average price is $1.47 and its 200-day moving average price is $2.69.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. During the same period last year, the business posted ($0.07) EPS. Geron's revenue was up 12927.3% compared to the same quarter last year.

Institutional Investors Weigh In On Geron

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Geron by 1.8% during the first quarter. Vanguard Group Inc. now owns 34,146,851 shares of the biopharmaceutical company's stock worth $54,293,000 after acquiring an additional 608,029 shares in the last quarter. Janus Henderson Group PLC raised its stake in Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company's stock worth $95,769,000 after acquiring an additional 4,516,615 shares in the last quarter. Wellington Management Group LLP raised its stake in Geron by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company's stock worth $47,826,000 after acquiring an additional 847,710 shares in the last quarter. Geode Capital Management LLC boosted its position in Geron by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 13,141,514 shares of the biopharmaceutical company's stock valued at $46,531,000 after buying an additional 73,515 shares in the last quarter. Finally, Woodline Partners LP boosted its position in Geron by 64.6% in the fourth quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company's stock valued at $41,019,000 after buying an additional 4,549,031 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.